teclistamab
genmab,janssen
['majestec-1', 'multiple myeloma', 'teclistamab']
majestec-1: teclistamab resulted in a high incidence of deep and durable response in patients with triple-class exposed relapsed or refractory multiple myeloma. #asco22 
The New England Journal of Medicine (https://t.co/YGfDrRsIhE) is the world’s leading medical journal and website.